Pemphigus vulgaris is a chronic autoimmune blistering disorder of skin and mucosal surfaces. Treatment consists mainly of corticosteroids given either in moderate to high oral doses or in the form of intravenous pulse therapy along with adjuvant immunosuppressant. Recently rituximab, an anti CD20 monoclonal antibody, has been approved as first line treatment. With recent advancements and targeted molecular therapies,treatment of pemphigus has been revolutionized. But looking at their high cost, pulse therapy with fewer side effects and with high and rapid remission rates, remains a treatment option in pemphigus in resource limited settings..